. . . "We granted Ortho Pharmaceutical Corporation (which has assigned its rights under the Product License Agreement to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, hereafter referred to as ??Johnson & Johnson??) a license to commercialize recombinant human erythropoietin as a human therapeutic in the United States in all markets other than dialysis (see ??Joint Ventures and Business" .